|
|
 |
|
Viewing report
|
|
|
|
FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster
GlobalData, March 2011, Pages: 5
FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster
Summary
GlobalData’s report, “FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster” provides key update on the landmark approval of the first lupus drug to be approved by FDA in more than 50 years, HGS/GlaxoSmithKline's Benlysta. It highlights the developmental history of the potential blockbuster drug and its road to approval. This report also highlights the other promising pipeline molecules for lupus.
Scope
- Benlysta - Developmental Overview, Clinical Trials and Road to Approval
- Future potential - Safety and efficacy concerns
- Promising late-stage pipeline for systemic lupus erythematosus
- Detailed product profiles of three most promising products
Reasons to buy
- Evaluate the future potential of the first FDA-approved lupus drug in 50 years as a new blockbuster.
- Understand the latest developments in the field of SLE therapeutics and exploit collaboration and partnership opportunities with the key players involved in the development of promising drugs for lupus.
- Develop entry strategies to further design product development, marketing and sales strategies in this promising field.
|
|
|
|
